[Chinese expert consensus on the use of fixed-combination antiglaucoma medications (2025)].

Abstract

Glaucoma, the leading cause of irreversible blindness worldwide, is a chronic and progressive disease requiring lifelong monitoring and treatment. To improve patient adherence and ensure the safe and effective use of multiple medications in the glaucoma management, fixed-combination antiglaucoma medications have emerged as a key therapeutic trend. In 2019, the Glaucoma Group of Ophthalmology Branch of Chinese Medical Association established a consensus on the use of fixed-combination antiglaucoma medications. Upon this foundation, updated consensus recommendations have been formulated through collaboration with the Glaucoma Group of Chinese Ophthalmologist Association. This revision incorporates a comprehensive review of domestic and international research advances over the past five years, along with clinical data analysis and in-depth discussions, aiming to further standardize the clinical practice associated with glaucoma.